Table 1.
Activity of VE-822 and gemcitabine in soft-tissue sarcoma cells.
| Cell line ID | Histological subtype | TP53 mutational status | MDM2 amplification status | IC50 VE-822 (µM) | IC50 Gemcitabine (nM) | Combination index | ALT * status |
|---|---|---|---|---|---|---|---|
| IB111 | Dedifferentiated liposarcoma | Wild-type | Amplified | 4.7 | 2.8 | 0.49 | positive |
| IB112 | Leiomyosarcoma | Null | Normal | 5.8 | 1.1 | 0.67 | positive |
| IB114 | Myxofibrosarcoma | Wild-type | Gain | 1.3 | 5.4 | 0.8 | negative |
| IB115 | Dedifferentiated liposarcoma | Wild-type | Amplified | 1.5 | 1.9 | 0.71 | positive |
| IB128 | Extra-skeletal osteosarcoma | Wild-type | Normal | 3.1 | 3.3 | 0.45 | negative |
| IB134 | Leiomyosarcoma | S215R | Gain | 12 | 3.7 | 0.96 | positive |
| IB136 | Leiomyosarcoma | Null | Gain | 5.1 | 8.2 | 0.5 | negative |
| 93T449 | Well differentiated liposarcoma | Wild-type | Amplified | 8 | 3.7 | 0.91 | negative |
*ALT: alternative lengthening telomere.